21 Mar 06
If Sales Force Effectiveness is high on your agenda in the current climate, then don’t miss Pharma IQ’s Next Generation Pharmaceutical Sales Strategies event in June. Learn from speakers who have effectively increased their sales force ROI & successfully implemented alternative options to drive sales effectiveness.
01 Mar 06
Genentech and Biogen Idec announced yesterday that the FDA has approved Rituxan (Rituximab) for use as a treatment of rheumatoid arthritis. Hopefully this news will mark the start of a new era in the treatment of autoimmune disease.
28 Feb 06
ICON’s core competency is project management, built up over the last fifteen years managing complex projects and underpinned by comprehensive and consistent processes which conform to the ISO9001:2000 quality certification.
24 Feb 06
Abbott recently had the largest gain in reputation of any company in its industry
when Fortune magazine ranked it number three in the magazine’s list of the
most admired companies in the United States – Fortune’s highest ranking for
Abbott since 1989. How was this achieved and what factors led up to it?
24 Feb 06
In an increasingly complex world, with significant changes taking place on a social,
commercial and economic basis almost weekly, corporate social responsibility is a
priority for Abbott as it engages its stakeholders, advances its core objectives and
exercises its influence – making productive contribution to the societies and
communities it operates in.
21 Feb 06
Today's edition of DailyUpdates features work conducted by Imperial College researchers who have identified an aptamer able to reduce the proliferation of lymphoma cells by 40%. This work represents a licensing opportunity. The aptamer is of potential therapeutic use and may be of interest to companies with an interest in biologic approach to oncology. The aptamers also forms the basis of a HTS assay that should help identify small molecule therapeutics for the treatment of hematological cancers
10 Feb 06
The approval of Novartis’ Glivec in 2001 represents one of the real success stories in the treatment of Chronic myeloid leukaemia. Already generating $2.2 billion in global sales (2005 figures), Glivec is Novartis’ second highest revenue generator and the continued development of this blockbuster seems certain to increase these figures still further. Here we focus on clinical studies aimed at advancing Gleevec as a treatment of small-cell lung cancer
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.